Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics and enlists all their major and minor projects
- The report assesses Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3BIGS Co LtdadvanceCor GmbH
AgeX Therapeutics Inc
Ascendia Pharmaceuticals Inc
AstraZeneca Plc
Athera Biotechnologies AB
Bayer AG
Beijing SH biotechnology Co Ltd
Bilix Co Ltd
Bio-Thera Solutions Ltd
Brillian Pharma Inc.
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
CeleCor Therapeutics Inc
Cell2Cure Aps
Cellix Bio Pvt Ltd
Chengdu Shibeikang Biomedical Technology Co Ltd
CSL Ltd
Cynata Therapeutics Ltd
DalCor Pharmaceuticals Inc
Dalian Wista Pharmaceutical Co Ltd
Diapin Therapeutics LLC
Eight Plus One Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
G&P Bioscience Co Ltd
Guangzhou Yipinhong Pharmaceutical Co Ltd
Han Wha Pharma Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Heqet Therapeutics Srl
Honya Medical Inc
Hyloris Pharmaceuticals SA
Imbria Pharmaceuticals Inc
Innolife Co Ltd
Jaan Biotherapeutics LLC
LipimetiX Development Inc
MabTics
Mandos LLC
MD Healthcare Inc
Novartis AG
Orion Corp
Pharmahungary Group
Regio Biosciences
Resverlogix Corp
Shanghai Pharmaceutical Group Co Ltd
Starpax Biopharma Inc
Tianjin Institute of Pharmaceutical Research
University of Debrecen
University of Oxford
Venturis Therapeutics Inc
Verseon Corp
VESSL Therapeutics Ltd
Virtual Drug Development Inc
XyloCor Therapeutics Inc
Yale University
Zhittya Genesis Medicine Inc